Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.

ABSTRACT:

Background

To report on radiation-related side effects and complications after ruthenium-106 plaque brachytherapy of uveal melanomas.

Methods

Medical records of 143 eyes with uveal melanoma, treated by ruthenium-106 brachytherapy between 1997 and 2012 at a single center, were analyzed. We evaluated the occurrence of radiation-related side effects on the anterior and posterior segment of the eye. The influence of patient, tumor and treatment parameters on outcome was analyzed by multivariate time to event analysis considering competing risks.

Results

The median overall follow-up was 37.9 months. After treatment, the estimated risk at 12, 24 and 48 months for developing anterior segment complications was 25.3%, 37.5% and 50.3% for cataract formation and 5.4%, 6.4% and 8

SUBMITTER: Tarmann L 

PROVIDER: S-EPMC5578662 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature